Loading...
Printed on 7/21/2026
For informational purposes only. This is not medical advice.
The Functional Assessment Staging Tool (FAST) is a functional staging framework for dementia progression, especially Alzheimer's disease, from normal function (stage 1) to very severe dependence (stage 7 sub-stages). It is commonly used for prognosis framing, care planning, and hospice-eligibility discussions.
Formula: Stage-based functional classification (1 to 7f), not a summed numeric score.
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
FAST stages progress from 1 (no functional impairment, normal adult) through 7f (very severe Alzheimer's disease with loss of all functional capacity). Stages 1-3 represent normal aging and mild cognitive impairment. Stage 4 reflects mild Alzheimer's disease with IADL deficits (difficulty with finances, complex cooking). Stage 5 indicates moderate Alzheimer's disease — the patient needs help choosing appropriate clothing but remains continent. Stage 6 (sub-stages a-e) marks moderately severe disease: progressive loss of dressing ability, bathing, toileting mechanics, then urinary incontinence (6d), then fecal incontinence (6e). Stage 7 (sub-stages a-f) represents very severe disease with progressive loss of verbal communication, ambulation, sitting, smiling, and finally the ability to hold the head up.
Stage the patient based on their current functional abilities and dependencies, using direct observation and caregiver collateral history. The FAST is best determined by asking specifically about each milestone in sequence: Can they manage finances independently? Choose their own clothing? Dress themselves? Bathe independently? Remain continent? Communicate in words? Walk independently? The stage is defined as the most advanced functional dependency consistently present. Note that individual patients may not follow the strictly sequential progression — 'functional substaging' where a patient skips or reverses substages is possible, particularly in non-Alzheimer dementias.
FAST staging informs care planning, family counseling, and prognosis discussions. Stages 4-5 signal the need to transition from IADL support to increasing ADL assistance. Stage 6 indicates moderate-to-heavy personal care needs, approaching nursing home level. Stage 7 indicates profound dependence consistent with end-stage disease. Reaching FAST stage 7a (fewer than 6 intelligible words per day) with at least one additional complicating condition (aspiration, pressure injury, pyelonephritis, septicemia, or fever over 10 days) is one of the criteria historically used to support hospice eligibility for Alzheimer's disease under the Medicare hospice benefit framework.
Geriatricians, neurologists, memory clinic physicians, families
FAST staging provides a shared vocabulary for communicating dementia progression over time that is more functionally grounded than cognitive test scores alone. Because families understand functional milestones (dressing, bathing, continence, communication) more intuitively than MMSE numbers, FAST staging facilitates clearer conversations about what to expect next, what level of care will be needed, and when to begin planning for transitions. Serial FAST staging at 6-12 month intervals creates a documented trajectory of decline.
Social workers, discharge planners, long-term care coordinators
FAST staging directly maps onto care intensity requirements. Stage 6 patients typically require 24-hour supervision and intensive personal care assistance that often exceeds what family caregivers can provide alone, supporting placement discussions. Stage 7 patients have nursing-home level care needs with specialized dementia care requirements. FAST staging provides objective, documented functional data that can support insurance authorization, care plan development, and placement decisions.
Hospice nurses, palliative physicians, social workers, ethics consultants
FAST stage 7a or beyond — combined with at least one complicating condition such as aspiration pneumonia, urinary tract infection, septicemia, pressure ulcers, or fever — has historically been used as a functional criterion for hospice eligibility in Alzheimer's disease under the U.S. Medicare hospice benefit. FAST staging supports conversations about goals of care, resuscitation preferences, and the appropriateness of comfort-focused versus disease-modifying treatment at end of life.
Geriatric social workers, dementia nurses, family physicians
FAST staging gives families a roadmap of expected functional decline that enables proactive planning for future care needs. Knowing that a patient currently at stage 5 will likely progress to incontinence (stage 6d-e) and eventually lose the ability to communicate verbally (stage 7) allows families to plan for residential care, power of attorney decisions, advance directives, and financial planning before crises arise.
Geriatricians, pharmacists, primary care clinicians
FAST staging is used to guide medication appropriateness decisions. Patients at stage 6 or 7 have minimal capacity to benefit from disease-modifying or cognitively-targeted pharmacotherapy but remain at significant risk from medication side effects. FAST staging supports deprescribing decisions for cholinesterase inhibitors, memantine, and preventive cardiovascular medications, shifting the therapeutic focus toward symptom management, comfort, and caregiver support.
A key strength of FAST is that it stages functional ability, which correlates more directly with care needs and caregiver burden than MMSE or MoCA scores alone. A patient with a low cognitive test score but preserved functional ability may be at a lower FAST stage — and require less intensive care — than a patient with a higher test score but significant functional dependencies.
FAST 7a (speech limited to approximately 6 intelligible words per day) is an important prognostic marker. Patients reaching this stage have a median survival typically under 12-18 months when accompanied by nutritional decline and complicating infections. This stage initiates conversations about hospice eligibility, goals of care, and the transition from active treatment to comfort-focused care.
FAST was developed for Alzheimer's disease, which typically follows a predictable sequence of functional loss. In frontotemporal dementia, Lewy body dementia, and vascular dementia, patients may lose functions in a different order — for example, retaining ADLs relatively well while losing executive function and language first. Apply FAST cautiously in these populations and acknowledge that stage descriptions may not map cleanly.
FAST stage 4 — difficulty with complex IADL tasks such as managing finances, planning complex meals, or traveling independently — may be subtle and overlap with normal aging variability. The key distinguishing feature is recent decline from a prior higher level of function, not simply the current functional level. Always anchor the staging in documented change from prior baseline.
FAST staging reflects functional status but does not capture the full clinical picture of dementia. Pair FAST with cognitive screening tools (MoCA, SLUMS) and neuropsychiatric symptom assessment (NPI-Q) for a comprehensive dementia evaluation. The combination of cognitive, functional, and behavioral information drives more accurate staging, care planning, and prognosis than any single tool.
The transition from stage 5 to stage 6 sub-stages represents a major inflection in caregiver burden. Each sub-stage (dressing, bathing, toileting, urinary incontinence, fecal incontinence) adds substantial physical and time demands. Identifying stage 6 progression helps anticipate when additional caregiver support services — adult day care, home health aide, respite care — should be proactively arranged.
The absolute FAST stage and the rate of progression between stages carry different prognostic information. A patient who has moved from stage 4 to stage 6 in 12 months is progressing more rapidly than one who took 3 years for the same progression. Rapid progressors have shorter prognosis and may reach end-stage sooner, with implications for advance care planning timelines.
FAST was developed by Barry Reisberg and published in 1988. Stage 7a or beyond combined with at least one specified complicating condition has historically supported Medicare hospice eligibility for Alzheimer's disease. FAST remains widely used in dementia care workflows, hospice-aligned staging discussions, and care planning contexts, particularly for functional trajectory tracking in Alzheimer's disease.
Higher FAST stages indicate more advanced functional dependence and greater long-term caregiving/support needs.
Use in longitudinal dementia care to structure stage communication, planning needs, and severity tracking.
FAST was developed around Alzheimer's disease progression and may map less cleanly to non-Alzheimer dementia patterns.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Classify SLUMS cognitive-screen totals (0-30) to support triage for fuller neurocognitive evaluation.
OpenMental HealthInterpret Montreal Cognitive Assessment (MoCA) scores. The leading cognitive screening tool for mild cognitive impairment and dementia.
OpenGeriatricsAssess independence in six basic activities of daily living with the Katz ADL Index. Scores range from 0 (dependent) to 6 (fully independent).
OpenGeriatricsAssess independence in higher-level daily tasks using the Lawton IADL scale (score 0-8).
Open